Glück Christian, Widmeier Eugen, Maier Sven, Staudacher Dawid L, Wengenmayer Tobias, Supady Alexander
Interdisciplinary Medical Intensive Care, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Straße 55, 79106, Freiburg, Germany.
Department of Cardiovascular Surgery, Heart Center, University of Freiburg, Freiburg, Germany.
Med Klin Intensivmed Notfmed. 2025 Jan 31. doi: 10.1007/s00063-024-01245-6.
Venovenous extracorporeal membrane oxygenation (VV ECMO) is an established support option for patients with very severe respiratory failure and played an important role during the coronavirus disease 2019 (COVID-19) pandemic. Bacteria and fungi can lead to severe infectious complications in critically ill patients. The aim of this study was to describe the microbiological spectrum of bacteria and fungi detected in patients with COVID-19-associated respiratory failure supported with VV ECMO in our center.
This retrospective single-center analysis included all patients with COVID-19-associated respiratory failure supported with VV ECMO in our center between March 2020 and May 2022. All findings from microbiological samples, taken as part of clinical routine assessment from initiation of VV ECMO until day 30 were included. Samples were described by site and time of detection and microbiological characteristics.
From March 2020 through May 2022, 88 patients with COVID-19-associated respiratory failure received VV ECMO support at our center. In 83/88 patients (94.3%), one or more pathogens were found in microbiological samples. Most pathogens were isolated from samples from the respiratory tract (88.6%). Earliest detection occurred in samples from the respiratory tract with a median time of 5 days to first detection. The most frequently detected pathogens were Staphylococcus spp., Candida spp., Klebsiella spp., Escherichia coli and Enterococcus spp.
In this cohort of severely ill COVID-19 patients receiving VV ECMO support, pathogens were frequently detected.
静脉-静脉体外膜肺氧合（VV ECMO）是治疗极重度呼吸衰竭患者的一种既定支持手段，在2019冠状病毒病（COVID-19）大流行期间发挥了重要作用。细菌和真菌可导致重症患者出现严重的感染性并发症。本研究的目的是描述在我们中心接受VV ECMO支持的COVID-19相关呼吸衰竭患者中检测到的细菌和真菌的微生物谱。
这项回顾性单中心分析纳入了2020年3月至2022年5月期间在我们中心接受VV ECMO支持的所有COVID-19相关呼吸衰竭患者。纳入了从开始VV ECMO至第30天作为临床常规评估一部分采集的微生物样本的所有检测结果。样本按检测部位、时间和微生物特征进行描述。
2020年3月至2022年5月，88例COVID-19相关呼吸衰竭患者在我们中心接受了VV ECMO支持。在83/88例患者（94.3%）的微生物样本中发现了一种或多种病原体。大多数病原体是从呼吸道样本中分离出来的（88.6%）。最早在呼吸道样本中检测到病原体，首次检测的中位时间为5天。最常检测到的病原体是葡萄球菌属、念珠菌属、克雷伯菌属、大肠杆菌和肠球菌属。
在这组接受VV ECMO支持的重症COVID-19患者中，经常检测到病原体。
